Cargando…

Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology

Background: The incidence of Nonalcoholic Fatty Liver (NAFL) is increasing year by year, growing evidence suggests that the intestinal flora plays a causative role in NAFL. Huazhi Rougan Granule (HRG) is commonly used in the clinical treatment of NAFL. It is reported that it can reduce lipids and pr...

Descripción completa

Detalles Bibliográficos
Autores principales: Liu, Yingying, Tan, Yingying, Huang, Jiaqi, Wu, Chao, Fan, Xiaotian, Stalin, Antony, Lu, Shan, Wang, Haojia, Zhang, Jingyuan, Zhang, Fanqin, Wu, Zhishan, Li, Bing, Huang, Zhihong, Chen, Meilin, Cheng, Guoliang, Mou, Yanfang, Wu, Jiarui
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086680/
https://www.ncbi.nlm.nih.gov/pubmed/35559233
http://dx.doi.org/10.3389/fphar.2022.875700
_version_ 1784704058957758464
author Liu, Yingying
Tan, Yingying
Huang, Jiaqi
Wu, Chao
Fan, Xiaotian
Stalin, Antony
Lu, Shan
Wang, Haojia
Zhang, Jingyuan
Zhang, Fanqin
Wu, Zhishan
Li, Bing
Huang, Zhihong
Chen, Meilin
Cheng, Guoliang
Mou, Yanfang
Wu, Jiarui
author_facet Liu, Yingying
Tan, Yingying
Huang, Jiaqi
Wu, Chao
Fan, Xiaotian
Stalin, Antony
Lu, Shan
Wang, Haojia
Zhang, Jingyuan
Zhang, Fanqin
Wu, Zhishan
Li, Bing
Huang, Zhihong
Chen, Meilin
Cheng, Guoliang
Mou, Yanfang
Wu, Jiarui
author_sort Liu, Yingying
collection PubMed
description Background: The incidence of Nonalcoholic Fatty Liver (NAFL) is increasing year by year, growing evidence suggests that the intestinal flora plays a causative role in NAFL. Huazhi Rougan Granule (HRG) is commonly used in the clinical treatment of NAFL. It is reported that it can reduce lipids and protect the liver, but no research has confirmed whether the drug’s effect is related to the intestinal flora. Therefore, we investigated whether the effect of HRG is related to the regulation of intestinal flora to further explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Methods: In this study, C57BL/6J mice were fed a high-fat diet for 10 weeks, and the high-fat diet plus HRG or polyene phosphatidylcholine capsules were each administered by gavage for 5 weeks. High-throughput sequencing, network pharmacology, and molecular docking were used to explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Results: HRG treatment can reduce body weight gain, lipid accumulation in liver and lipogenesis and reduce serum biochemical indexes in high-fat-fed mice. Analysis of intestinal flora showed that HRG changed the composition of intestinal flora, which was characterized by a decrease in the Firmicutes/Bacteroidetes ratio. Moreover, the species distribution was significantly correlated with AKP, HDL-C, and TG. Metagenetic analysis showed that HRG altered the functional composition and functional diversity of microorganisms, which was mainly characterized by an increase in the abundance of metabolic pathways. The network pharmacology results show that the mechanism of HRG in the treatment of NAFL through intestinal flora is mainly reflected in the biological process of gene function and related to infectious diseases, immune systems, and signal transduction pathways, such as cytokine-cytokine receptor interaction, Chagas disease, IL-17 signaling pathway and other signaling pathways. Conclusion: These results strongly suggest that HRG may alleviate NAFL by preventing IFD.
format Online
Article
Text
id pubmed-9086680
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-90866802022-05-11 Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology Liu, Yingying Tan, Yingying Huang, Jiaqi Wu, Chao Fan, Xiaotian Stalin, Antony Lu, Shan Wang, Haojia Zhang, Jingyuan Zhang, Fanqin Wu, Zhishan Li, Bing Huang, Zhihong Chen, Meilin Cheng, Guoliang Mou, Yanfang Wu, Jiarui Front Pharmacol Pharmacology Background: The incidence of Nonalcoholic Fatty Liver (NAFL) is increasing year by year, growing evidence suggests that the intestinal flora plays a causative role in NAFL. Huazhi Rougan Granule (HRG) is commonly used in the clinical treatment of NAFL. It is reported that it can reduce lipids and protect the liver, but no research has confirmed whether the drug’s effect is related to the intestinal flora. Therefore, we investigated whether the effect of HRG is related to the regulation of intestinal flora to further explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Methods: In this study, C57BL/6J mice were fed a high-fat diet for 10 weeks, and the high-fat diet plus HRG or polyene phosphatidylcholine capsules were each administered by gavage for 5 weeks. High-throughput sequencing, network pharmacology, and molecular docking were used to explore the mechanism of HRG in the treatment of NAFL through intestinal flora. Results: HRG treatment can reduce body weight gain, lipid accumulation in liver and lipogenesis and reduce serum biochemical indexes in high-fat-fed mice. Analysis of intestinal flora showed that HRG changed the composition of intestinal flora, which was characterized by a decrease in the Firmicutes/Bacteroidetes ratio. Moreover, the species distribution was significantly correlated with AKP, HDL-C, and TG. Metagenetic analysis showed that HRG altered the functional composition and functional diversity of microorganisms, which was mainly characterized by an increase in the abundance of metabolic pathways. The network pharmacology results show that the mechanism of HRG in the treatment of NAFL through intestinal flora is mainly reflected in the biological process of gene function and related to infectious diseases, immune systems, and signal transduction pathways, such as cytokine-cytokine receptor interaction, Chagas disease, IL-17 signaling pathway and other signaling pathways. Conclusion: These results strongly suggest that HRG may alleviate NAFL by preventing IFD. Frontiers Media S.A. 2022-04-26 /pmc/articles/PMC9086680/ /pubmed/35559233 http://dx.doi.org/10.3389/fphar.2022.875700 Text en Copyright © 2022 Liu, Tan, Huang, Wu, Fan, Stalin, Lu, Wang, Zhang, Zhang, Wu, Li, Huang, Chen, Cheng, Mou and Wu. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Pharmacology
Liu, Yingying
Tan, Yingying
Huang, Jiaqi
Wu, Chao
Fan, Xiaotian
Stalin, Antony
Lu, Shan
Wang, Haojia
Zhang, Jingyuan
Zhang, Fanqin
Wu, Zhishan
Li, Bing
Huang, Zhihong
Chen, Meilin
Cheng, Guoliang
Mou, Yanfang
Wu, Jiarui
Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
title Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
title_full Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
title_fullStr Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
title_full_unstemmed Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
title_short Revealing the Mechanism of Huazhi Rougan Granule in the Treatment of Nonalcoholic Fatty Liver Through Intestinal Flora Based on 16S rRNA, Metagenomic Sequencing and Network Pharmacology
title_sort revealing the mechanism of huazhi rougan granule in the treatment of nonalcoholic fatty liver through intestinal flora based on 16s rrna, metagenomic sequencing and network pharmacology
topic Pharmacology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9086680/
https://www.ncbi.nlm.nih.gov/pubmed/35559233
http://dx.doi.org/10.3389/fphar.2022.875700
work_keys_str_mv AT liuyingying revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT tanyingying revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT huangjiaqi revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT wuchao revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT fanxiaotian revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT stalinantony revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT lushan revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT wanghaojia revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT zhangjingyuan revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT zhangfanqin revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT wuzhishan revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT libing revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT huangzhihong revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT chenmeilin revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT chengguoliang revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT mouyanfang revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology
AT wujiarui revealingthemechanismofhuazhirougangranuleinthetreatmentofnonalcoholicfattyliverthroughintestinalflorabasedon16srrnametagenomicsequencingandnetworkpharmacology